Table 5: Medication use at presentation, discharge and follow-up.
| Medication | Prior to presentation; no. (%) of patients |
At time of discharge;* no. (%) of patients |
At 90 d post-MI;† no. (%) of patients |
|---|---|---|---|
| n = 2181 | n = 2043 | n = 1839 | |
| ACE + ARB inhibitor |
636 (29.2) |
1740 (85.2) |
1431 (77.8) |
| Statin |
552 (25.3) |
1878 (91.9) |
1585 (86.2) |
| ASA |
445 (20.4) |
1957 (95.8) |
1622 (88.2) |
| ACE inhibitor |
435 (19.9) |
1622 (79.4) |
1308 (71.1) |
| β-Blocker |
343 (15.7) |
1743 (85.3) |
1396 (75.9) |
| ARB inhibitor |
215 (9.9) |
125 (6.1) |
143 (7.8) |
| Clopidogrel |
106 (4.9) |
1688 (82.6) |
1415 (76.9) |
| Warfarin | 43 (2.0) | 133 (6.5) | 94 (5.1) |
Note: ACE = angiotensin-converting-enzyme, ARB = angiotensin II receptor blocker, ASA = acetylsalicylic acid, MI = myocardial infarction. *Data exclude patients who died prior to treatment and those already admitted when the STEMI occurred. †Data exclude patients who died or were lost to follow-up.